These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11005706)

  • 41. Toward improved pregnancy labelling.
    Koren G; Sakaguchi S; Klieger C; Kazmin A; Osadchy A; Yazdani-Brojeni P; Matok I
    J Popul Ther Clin Pharmacol; 2010; 17(3):e349-57. PubMed ID: 21041868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The U.S. Food and Drug Adminstration (FDA) has assigned pregnancy category D to valproate.
    Peckman H
    N C Med J; 2010; 71(4):396-8. PubMed ID: 21155112
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparing drug classification systems.
    Mahoney A; Evans J
    AMIA Annu Symp Proc; 2008 Nov; ():1039. PubMed ID: 18999016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review.
    Macklis PC; Dulmage B; Evans B; Rosenbach M; Gudjonsson JE; Kaffenberger BH
    Drugs R D; 2020 Sep; 20(3):171-187. PubMed ID: 32557274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring for teratogenic signals: pregnancy registries and surveillance methods.
    Howard TB; Tassinari MS; Feibus KB; Mathis LL
    Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):209-14. PubMed ID: 21766431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical value of FDA class C drugs approved from 1981 to 1988.
    Yasuda SU; Woosley RL
    Clin Pharmacol Ther; 1992 Dec; 52(6):577-82. PubMed ID: 1458766
    [No Abstract]   [Full Text] [Related]  

  • 47. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacology consultation: a better answer to safety issues of drug therapy during pregnancy?
    Erdeljić V; Francetić I; Makar-Ausperger K; Likić R; Radacić-Aumiler M
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1037-46. PubMed ID: 20644922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discrepancies in the Evidence and Recommendation Levels of Pregnancy Information in Prescription Drug Labeling in the United States, United Kingdom, Japan, and Korea.
    Noh Y; Yoon D; Song I; Jeong HE; Bae JH; Shin JY
    J Womens Health (Larchmt); 2018 Sep; 27(9):1086-1092. PubMed ID: 29878862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of foetal risk associated with 93 non-US-FDA approved medications during pregnancy.
    Al-Jedai AH; Balhareth SS; Algain RA
    Saudi Pharm J; 2012 Oct; 20(4):287-99. PubMed ID: 23960803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug use in pregnancy: how to avoid problems.
    Rao JM; Arulappu R
    Drugs; 1981 Nov; 22(5):409-14. PubMed ID: 6120825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The drug development process and the pregnant woman.
    Frederiksen MC
    J Midwifery Womens Health; 2002; 47(6):422-5. PubMed ID: 12484663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PregTox: A Resource of Knowledge about Drug Fetal Toxicity.
    Chen Q; Gan Y; Wang K; Li Q
    Biomed Res Int; 2022; 2022():4284146. PubMed ID: 35469349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
    Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
    Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different black box warning labeling for same-class drugs.
    Panagiotou OA; Contopoulos-Ioannidis DG; Papanikolaou PN; Ntzani EE; Ioannidis JP
    J Gen Intern Med; 2011 Jun; 26(6):603-10. PubMed ID: 21286838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Knowledge transfer and translation: examining how teratogen information is disseminated.
    Shahin I; Einarson A
    Birth Defects Res A Clin Mol Teratol; 2011 Nov; 91(11):956-61. PubMed ID: 21948595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity.
    Wiśniowska B; Polak S
    Drug Discov Today; 2017 Jan; 22(1):10-16. PubMed ID: 27717849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.